Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$105.19 USD
+0.31 (0.30%)
Updated Dec 4, 2023 04:00 PM ET
After-Market: $105.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Abbott (ABT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$118.69 | $133.00 | $103.00 | 13.17% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Abbott comes to $118.69. The forecasts range from a low of $103.00 to a high of $133.00. The average price target represents an increase of 13.17% from the last closing price of $104.88.
Analyst Price Targets (16)
Broker Rating
Abbott currently has an average brokerage recommendation (ABR) of 1.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.56 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 11.11% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 11.11%.
Broker Rating Breakdown

Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.56 | 1.56 | 1.56 | 1.56 | 1.56 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/20/2023 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
10/18/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/17/2023 | Mizuho SecuritiesUSA | Anthony Petrone | Hold | Hold |
7/21/2023 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
4/17/2023 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.56 |
ABR (Last week) | 1.56 |
# of Recs in ABR | 18 |
Average Target Price | $118.69 |
LT Growth Rate | 9.00% |
Industry | Medical - Products |
Industry Rank by ABR | 144 of 252 |
Current Quarter EPS Est: | 1.19 |